Renal Cancer - Pipeline Insight, 2024

This “Renal Cancer - Pipeline Insight, 2024,”report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Renal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Renal Cancer Understanding

Renal Cancer: Overview

Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth. Renal cell carcinoma is the most common type of adult kidney cancer. It is responsible for approximately 85% of kidney neoplasms. Renal cell carcinoma may be clinically asymptomatic for the majority of its course.

Only 10% of patients have the traditional triad of flank pain, hematuria, and flank mass. In approximately 33% of cases, renal cell cancer (RCC) patients develop metastatic spread. The lack of significant efficacy from available therapies complicates the clinical management of patients with metastatic RCC.

Early on, renal cell carcinoma usually does not cause any symptoms. However, as the disease progress, the common metastatic renal cell carcinoma symptoms include low back pain, fever, night sweats, high blood pressure, and others.

There are many risk factors also associated with renal cancer these include body weight and height, smoking other kidney disease like people suffering with kidney failure condition the genetic and inherited patterns people with a first degree relative who have been diagnosed with kidney cancer have roughly double the risk of developing renal cell carcinoma, high blood pressure, thyroid cancer and diabetic patients.

The diagnosis and treatment plan for renal carcinoma includes physical examination, CT scans, complete blood count, urine examination, biopsy, and other than this targeted drug therapy; targeted therapy includes treatments that attack specific things cancers need to survive, like a tumor’s blood vessels or certain proteins; these include axitinib (Inlyta), bevacizumab (Avastin), cabozantinib (Cometriq), everolimus (Afinitor), lenvatinib (Lenvima), nivolumab (Opdivo), pazopanib (Votrient), sorafenib (Nexavar), sunitinib (Sutent), and temsirolimus (Torisel) and immunotherapy, chemotherapy also may contribute to the diagnosis of renal cell carcinoma.

Renal Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Renal Cancer pipeline landscape is provided which includes the disease overview and Renal Cancer treatment guidelines. The assessment part of the report embraces, in depth Renal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Renal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Renal Cancer.

Renal Cancer Emerging Drugs Chapters

This segment of the Renal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal Cancer Emerging Drugs

Atezolizumab : Genentech Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat RenalCancer.

Olaparib: Astra ZenecaOlaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase IIstudies.

MK-4830 : Merck & Co., Inc MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of RenalCancer.

ALLO-316 : Allogene Therapeutics ALLO-316, an Allo CAR T™ investigational product that targets CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors the drug candidate has received Fast Track Designation (FTD) from U.S FDA based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinoma. The drug is in Phase I stage of clinicaltrials.

Renal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Renal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Renal Cancer

There are approx. 75+ key companies which are developing the therapies for Renal Cancer. The companies which have their Renal Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech

Phases

This report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Renal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal Cancer drugs.

Renal Cancer Report Insights

• Renal Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Renal Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Renal Cancer drugs?
• How many Renal Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Renal Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Genentech
• AstraZeneca
• Allogene Therapeutics
• Merck & Co., Inc
• X4 Pharmaceuticals
• Argos Therapeutics
• Pfizer
• Eisai Inc.
• Merck Sharp & Dohme LLC
• Bristol-Myers Squibb
• AVEO Pharmaceuticals, Inc
• Mabwell (Shanghai) Bioscience Co., Ltd.
• Beijing Scitech-Mq Pharmaceuticals Limited
• Qilu Pharmaceutical Co., Ltd.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.

Key Products

• Atezolizumab
• Olaparib
• ALLO-316
• MK-4830
• X4P-001
• CMN-001
• Axitinib
• Lenvatinib
• Pembrolizumab
• Nivolumab
• Tivozanib
• 6MW3211
• ST-1898
• QL1706
• HS-10516

This product will be delivered within 1-3 business days.